Gemcitabine and oxaliplatin combination chemotherapy for metastatic well‐differentiated neuroendocrine carcinomas |
| |
| Authors: | Philippe A. Cassier MD Thomas Walter MD Beatrice Eymard MD Philippe Ardisson MD Maurice Perol MD Carole Paillet MD Jean‐Alain Chayvialle MD PhD Jean‐Yves Scoazec MD PhD Valerie Hervieu MD PhD Catherine Lombard Bohas MD |
| |
| Affiliation: | 1. Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France;2. Lyon University‐UCBL, Villeurbanne, France;3. Gastroenterology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France;4. Gastroenterology Department, Lucien Hussel Hospital, Vienne, France;5. Medical Oncology, Sauvegarde Private Hospital, Lyon, France;6. Pneumology Department, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France;7. Pharmacy Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France;8. Pathology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France |
| |
| Abstract: | ![]()
BACKGROUND: Beyond the usual regimens based on streptozocin and doxorubicin or 5‐fluorouracil, no second‐line therapy of metastatic neuroendocrine tumor has gained wide acceptance. Gemcitabine and oxaliplatin are generally well tolerated and have shown activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine‐oxaliplatin combination (GEMOX) in the treatment of patients with metastatic neuroendocrine tumors. METHODS: Twenty consecutive patients with progressive disease were treated with GEMOX, in most cases after failure of other chemotherapy regimens (median = 2). Patients were followed for evidence of toxicity, response, and survival. Two patients were chemotherapy‐naive at treatment initiation and were excluded from the efficacy analysis. RESULTS: Toxicity was manageable overall; however, 6 (30%) patients had to discontinue treatment because of oxaliplatin‐induced neurotoxicity (grade 2). Three (17%) of 18 patients had a partial response, median progression‐free survival was 7.0 months, and median overall survival was 23.4 months. CONCLUSIONS: Gemcitabine‐oxaliplatin combination shows interesting activity and is well tolerated in pretreated patients with neuroendocrine tumors. Cancer 2009. © 2009 American Cancer Society. |
| |
| Keywords: | neuroendocrine tumors gemcitabine oxaliplatin chemotherapy |
|
|
